Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson’s disease

References

• Jankovic J, Tintner R. Dystonia and parkinsonism. Parkinsonism Relat. Disord.8, 109–121 (2001).
   PubMed Web of Science ®Google Scholar
• Nutt JG, Wooten GF. Clinical practice. Diagnosis and initial management of Parkinson’s disease. N. Engl. J. Med.353, 1021–1027 (2005).
   PubMed Web of Science ®Google Scholar
• Diamond A. Jankovic J. Treatment of advanced Parkinson’s disease. Expert Rev. Neurother.6(8), 1181–1197 (2006).
   PubMedGoogle Scholar
• Suchowersky O, Rich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Diagnosis and prognosis of new onset Parkinson disease: report of the Quality Standards Subcommittee of the American academy of Neurology. Neurology66, 968–975 (2006).
   PubMed Web of Science ®Google Scholar
• Jankovic J, Schwartz KS, Ondo W. Re-emergent tremor of Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr.67, 646–650 (1999).
   PubMed Web of Science ®Google Scholar
• Elble RJ. Tremor and dopamine agonists. Neurology58(4 Suppl. 1), S57–S62 (2002).
   Google Scholar
• Jankovic J, Schwartz K. Botulinum toxin treatment of tremors. Neurology41, 1185–1188 (1991).
   PubMed Web of Science ®Google Scholar
• Trosch RM, Pullman SC. Botulinum toxin A injections for the treatment of hand tremor. Mov. Disord.9, 601–609 (1994).
   PubMedGoogle Scholar
• Henderson JM, Ghika JA, Van-Melle G, Haller E, Einstein R. Botulinum toxin A in nondystonic tremors. Eur. Neurol.36, 29–35 (1996).
   PubMedGoogle Scholar
• Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized double-blind, placebo controlled study to evaluate botulinum toxin A in essential hand tremor. Mov. Disord.11, 250–256 (1996).
   PubMed Web of Science ®Google Scholar
• Pullman SC, Greene P, Pahn S et al. Approach to the treatment of limb disorders with botulinum toxin A: experience with 187 patients. Arch. Neurol.53, 617–624 (1996).
   PubMedGoogle Scholar
• Brin MF, Lyons KE, Doucette J et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology56, 1523–1528 (2001).
   PubMed Web of Science ®Google Scholar
• Pahwa R, Busenbark K, Swanson-Hyland EF et al. Botulinum toxin treatment of essential head tremor. Neurology45(4), 822–824 (1995).
   PubMed Web of Science ®Google Scholar
• Wissel J, Masuhr F, Schelosky L, Ebersbach G, Poewe W. Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor. Mov. Disord.12(5), 722–726 (1997).
   PubMedGoogle Scholar
• Warrick P, Dromey C, Irish JC, Durkin L, Pakiam A, Lang A. Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection. Laryngoscope110(8), 1366–1374 (2000).
   PubMed Web of Science ®Google Scholar
• Adler CH, Bansberg SF, Hentz JG et al. Botulinum toxin type A for treating voice tremor. Arch. Neurol.61(9), 1416–1420 (2004).
   PubMed Web of Science ®Google Scholar
• Hunker CJ, Abbs JH. Uniform frequency of parkinsonian resting tremor in the lips, jaw, tongue and index finger. Mov. Disord.5, 71–77 (1990).
   PubMedGoogle Scholar
• Salamone JD, Mayorga AJ, Trevitt JT, Cousins MS, Conlan A, Nawab A. Tremulous jaw movements in rats: a model of parkinsonian tremor. Prog. Neurobiol.56(6), 591–611 (1998).
   PubMedGoogle Scholar
• Schneider SA, Edwards MJ, Cordivari C, Macleod WN, Bhatia KP. Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson’s disease. Mov. Disord.21(10), 1722–1724 (2006).
   PubMedGoogle Scholar
• Kidron D, Melamed E. Forms of dystonia in patients with Parkinson’s disease. Neurology37, 1009–1011 (1987).
   PubMed Web of Science ®Google Scholar
• Hartmann A, Pogarell O, Oertel WH. Secondary dystonia. J. Neurol.245, 511–518 (1998).
   PubMed Web of Science ®Google Scholar
• Quinn NP. Parkinsonism and dystonia, pseudoparkinsonism and pseudodystonia. Adv. Neurol.60, 540–543 (1993).
   PubMedGoogle Scholar
• Tabamo REJ, Fernandez HH, Friedman J, Simon DK. Young-onset Parkinson’s disease: a clinical pathologic description of two siblings. Mov. Disord.13, 744–746 (2000).
   Google Scholar
• Poewe WH, Lees AJ, Stern GM. Dystonia in Parkinson’s disease: clinical and pharmacological features. Ann. Neurol.23, 73–78 (1988).
   PubMed Web of Science ®Google Scholar
• Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov. Disord.20(Suppl. 11), S11–S16 (2005).
   PubMed Web of Science ®Google Scholar
• Jankovic J. Complications and limitations of drug therapy for Parkinson’s disease. Neurology55(12 Suppl. 6), S2–S6 (2000).
   PubMed Web of Science ®Google Scholar
• Ashour R, Tintner R, Jankovic J. Striatal deformities of the hand and foot in Parkinson’s disease. Lancet Neurol.4(7) 423–431 (2005).
   PubMedGoogle Scholar
• Vidailhet M, Bonnet AM, Marconi R, Gouider-Khouja N, Agid Y. Do parkinsonian symptoms and levodopa-induced dyskinesias start in the foot? Neurology44, 1613–1616 (1994).
   PubMedGoogle Scholar
• Pacchetti C, Albani G, Martignoni E, Godi L, Alfonsi E, Nappi G. “Off” painful dystonia in Parkinson’s disease treated with botulinum toxin. Mov. Disord.10(3), 333–336 (1995).
   PubMed Web of Science ®Google Scholar
• Limousin P, Memin B, Pollak P. Treatment of dystonia occurring in parkinsonian syndromes by botulinum toxin. Eur. Neurol.37, 66–67 (1997).
   PubMedGoogle Scholar
• Jankovic J. Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiatr.75(7), 951–957 (2004).
   PubMed Web of Science ®Google Scholar
• Giladi N, Meer J, Honigman S. The use of botulinum toxin to treat “striatal” toes. J. Neurol. Neurosurg. Psychiatr.57(5), 659 (1994).
   PubMedGoogle Scholar
• Cordivari C, Misra VP, Catania S, Lees AJ. Treatment of dystonic clenched fist with botulinum toxin. Mov. Disord.16, 907–913 (2001).
   PubMed Web of Science ®Google Scholar
• Soonawala N, Bhatia KP, Yeung JHM et al. Idiopathic blepharospasm does not lead to a parkinsonian syndrome: results of a questionnaire-based follow-up study. J. Neurol.246, 283–286 (1999).
   PubMedGoogle Scholar
• Krack P, Marion MH. ‘Apraxia of lid opening.’ A focal eyelid dystonia: clinical study of 32 patients. Mov. Disord.9, 610–615 (1994).
   PubMed Web of Science ®Google Scholar
• Jankovic J. Apraxia of lid opening. Mov. Disord.10, 686 (1995).
   PubMed Web of Science ®Google Scholar
• Boghen D. Apraxia of lid opening: a review. Neurology48, 1491–1494 (1997).
   PubMedGoogle Scholar
• Katz BB, Rosenberg JH. Botulinum therapy for apraxia of eyelid opening. Am. J. Ophthalmol.103, 718–719 (1987).
   PubMedGoogle Scholar
• Lepore V, Defazio G, Acquistapace D et al. Botulinum A toxin for the so-called apraxia of lid opening. Mov. Disord.10, 525–526 (1995).
   PubMed Web of Science ®Google Scholar
• Aramideh M, Ongerboer de Visser BW, Brans JW, Koelman JH, Speelman JD. Pretarsal application of botulinum toxin for treatment of blepharospasm. J. Neurol. Neurosurg. Psychiatr.59(3), 309–311 (1995).
   PubMed Web of Science ®Google Scholar
• Forget R, Tozlovanu V, Iancu A, Boghen D. Botulinum toxin improves lid opening delays in blepharospasm-associated apraxia of lid opening. Neurology58(12), 1843–1846 (2002).
   PubMed Web of Science ®Google Scholar
• Aramideh M, Ongerboer de Visser BW, Brans JW, Koelman JH, Speelman JD. Pretarsal application of botulinum toxin for treatment of blepharospasm. J. Neurol. Neurosurg. Psychiatr.59(3), 309–311 (1995).
   PubMed Web of Science ®Google Scholar
• Roggenkamper P, Jost WH, Bihari K, Comes G, Grafe S; for the NT 201 Blepharospasm Study Team. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J. Neural Transm.113(3), 303–312 (2006).
   PubMed Web of Science ®Google Scholar
• Lobbezoo F, Lavigne GJ, Tanguay R, Montplaisir JY. The effect of the catecholamine precursor L-dopa on sleep bruxism: a controlled clinical trial. Mov. Disord.12, 73–78 (1997).
   PubMed Web of Science ®Google Scholar
• Lobbezoo F, Soucy JP, Hartman NG, Montplaisir JY, Lavigne GJ. Effects of the dopamine D2 receptor agonist bromocriptine on sleep bruxism: report of two single-patient clinical trials. J. Dent. Res.76, 1610–1614 (1997).
   PubMed Web of Science ®Google Scholar
• Magee KR. Bruxism related to levodopa therapy. JAMA214, 147 (1970).
   PubMed Web of Science ®Google Scholar
• Wooten-Watts MW, Tan EK, Jankovic J. Bruxism and cranial-cervical dystonia: is there a relationship? Cranio.17, 196–201 (1999).
   PubMedGoogle Scholar
• Harada T, Ichiki R, Tsukiyama Y, Koyano K. The effect of oral splint devices on sleep bruxism: a 6-week observation with an ambulatory electromyographic recording device. J. Oral Rehabil.33(7), 482–488 (2006).
   PubMed Web of Science ®Google Scholar
• Van Zandijcke M, Marchau MM. Treatment of bruxism with botulinum toxin injections. J. Neurol. Neurosurg. Psychiatr.53(6), 530 (1990).
   PubMed Web of Science ®Google Scholar
• Ivanhoe CB, Lai JM, Francisco GE. Bruxism after brain injury: successful treatment with botulinum toxin-A. Arch. Phys. Med. Rehabil.78(11), 1272–1273 (1997).
   PubMed Web of Science ®Google Scholar
• Pidcock FS, Wise JM, Christensen JR. Treatment of severe post-traumatic bruxism with botulinum toxin-A: case report. J. Oral Maxillofac. Surg.60(1), 115–117 (2002).
   PubMed Web of Science ®Google Scholar
• See SJ, Tan EK. Severe amphethamine-induced bruxism: treatment with botulinum toxin. Acta Neurol. Scand.107(2), 161–163 (2003).
   PubMed Web of Science ®Google Scholar
• Nash MC, Ferrell RB, Lombardo MA, Williams RB. Treatment of bruxism in Huntington’s disease with botulinum toxin. J. Neuropsychiatry Clin. Neurosci.16(3), 381–382 (2004).
   PubMed Web of Science ®Google Scholar
• Monroy PG, da Fonseca MA. The use of botulinum toxin-A in the treatment of severe bruxism in a patient with autism: a case report. Spec. Care Dentist.26(1), 37–39 (2006).
   PubMedGoogle Scholar
• Tan E-K, Jankovic J. Treating severe bruxism with botulinum toxin. J. Am. Dent. Assoc.131, 211–216 (2000).
   PubMed Web of Science ®Google Scholar
• Djaldetti R, Mosberg-Galili H, Sroka H, Merims D, Melamed E. Camptocormia (bent spine) in patients with Parkinson’s disease – characterization and possible pathogenesis of an unusual phenomenon. Mov. Disord.14, 443–447 (1999).
   PubMed Web of Science ®Google Scholar
• Azher SN, Jankovic J. Camptocormia: pathogenesis, classification, and response to therapy. Neurology65(3), 355–359 (2005).
   PubMed Web of Science ®Google Scholar
• Wunderlich S, Csoti I, Reiners K et al. Camptocormia in Parkinson’s disease mimicked by focal myositis of the paraspinal muscles. Mov. Disord.17(3), 598–600 (2002).
   PubMed Web of Science ®Google Scholar
• Feriha O, Aytul M, Hasan M. A case of camptocormia (bent spine) secondary to early motor neuron disease. Behav. Neurol.15(1–2), 51–54 (2004).
   PubMedGoogle Scholar
• Diederich NJ, Goebel HH, Dooms G et al. Camptocormia associated with focal myositis in multiple-system atrophy. Mov. Disord.21(3), 390–394 (2006).
   PubMedGoogle Scholar
• Ozer F, Ozturk O, Meral H, Serdaroglu P, Yayla V. Camptocormia in a patient with parkinson disease and a myopathy with nemaline rods. Am. J. Phys. Med. Rehabil.86(1), 3–6 (2007).
   PubMedGoogle Scholar
• Slawek J, Derejko M, Lass P. Camptocormia as a form of dystonia in Parkinson’s disease. Eur. J. Neurol.10(1), 107–108 (2003).
   PubMedGoogle Scholar
• Holler I, Dirnberger G, Pirker W, Auff E, Gerschlager W. Camptocormia in idiopathic Parkinson’s disease: [(123)I]β-CIT SPECT and clinical characteristics. Eur. Neurol.50(2), 118–120 (2003).
   PubMedGoogle Scholar
• Djaldetti R, Melamed E. Camptocormia in Parkinson’s disease: new insights. J. Neurol. Neurosurg. Psychiatr.77(11), 1205 (2006).
   PubMedGoogle Scholar
• Lepoutre AC, Devos D, Blanchard-Dauphin A et al. A specific clinical pattern of camptocormia in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr.77(11), 1229–1234 (2006).
   PubMed Web of Science ®Google Scholar
• Melamed E, Djaldetti R. Camptocormia in Parkinson’s disease. J. Neurol.253(Suppl. 7), vii14–vii16 (2006).
   PubMedGoogle Scholar
• Nandi D, Parkin S, Scott R et al. Camptocormia treated with bilateral pallidal stimulation. J. Neurosurg.97(2), 461–466 (2002).
   PubMedGoogle Scholar
• Micheli F, Cersosimo MG, Piedimonte F. Camptocormia in a patient with Parkinson disease: beneficial effects of pallidal deep brain stimulation. Case report. J. Neurosurg.103(6), 1081–1083 (2005).
   PubMedGoogle Scholar
• Hellmann MA, Djaldetti R, Israel Z, Melamed E. Effect of deep brain subthalamic stimulation on camptocormia and postural abnormalities in idiopathic Parkinson’s disease. Mov. Disord.21(11), 2008–2010 (2006).
   PubMedGoogle Scholar
• Denny-Brown D. The nature of apraxia. J. Nerv. Ment. Dis.126, 9–31 (1958).
   PubMed Web of Science ®Google Scholar
• Langworthy OR. A review of the studies of Derek Denny-Brown In: The Sensory Control Of Posture and Movement. Williams and Wilkins, MD, USA 121–122 (1970).
   Google Scholar
• Giladi N, Treves TA, Simon ES et al. Freezing of gait in patients with advanced Parkinson’s disease. J. Neural Transm.108, 53–61 (2001).
   PubMed Web of Science ®Google Scholar
• Krack P, Batir A, Van Blercom N et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N. Engl. J. Med.349(20), 1925–1934 (2003).
   PubMed Web of Science ®Google Scholar
• Davis JT, Lyons KE, Pahwa R. Freezing of gait after bilateral subthalamic nucleus stimulation for Parkinson’s disease. Clin. Neurol. Neurosurg.108(5), 461–464 (2006).
   PubMed Web of Science ®Google Scholar
• Giladi N, Honigman S. Botulinum toxin injections to one leg alleviate freezing of gait in a patient with Parkinson’s disease. Mov. Disord.12(6), 1085–1086 (1997).
   PubMedGoogle Scholar
• Giladi N, Gurevich, Shabtai H, Paleacu D, Simon ES. The effect of botulinum toxin injections to the calf muscles on freezing of gait in parkinsonism: a pilot study. J. Neurol.248, 572–576 (2001).
   PubMedGoogle Scholar
• Fernandez HH, Lannon MC, Trieschmann ME, Friedman JH. Botulinum toxin type B for gait freezing in Parkinson’s disease. Med. Sci. Monit.10(7), 282–284 (2004).
   Google Scholar
• Wieler M, Camicioli R, Jones CA, Martin WR. Botulinum toxin injections do not improve freezing of gait in Parkinson disease. Neurology65(4), 626–628 (2005).
   PubMedGoogle Scholar
• Gurevich T, Peretz C, Moore O, Weizmann N, Giladi N. The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson’s disease: a double blind placebo-controlled pilot study. Mov. Disord.22(6), 880–883 (2007).
   PubMedGoogle Scholar
• Kupsky WJ, Grimes MM, Sweeting J, Bertsch R, Cote LJ. Parkinson’s disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology37, 1253–1255 (1987).
   PubMed Web of Science ®Google Scholar
• Proulx de Courval FP, Wiseman MA, Panisset M. Salivary production in Parkinson’s disease. Mov. Disord.20, 204–247 (2005).
   PubMedGoogle Scholar
• Pinnington LL, Muhiddin KA, Ellis RE, Playford ED. Non-invasive assessment of swallowing and respiration in Parkinson’s disease. J. Neurol.247(10), 773–777 (2000).
   PubMedGoogle Scholar
• Leopold NA, Kagel MC. Pharyngo-esophageal dysphagia in Parkinson’s disease. Dysphagia12, 1–18 (1997).
   Google Scholar
• Tscheng DZ. Sialorrhea – therapeutic drug options. Ann. Pharmacother.36, 1785–1790 (2002).
   PubMed Web of Science ®Google Scholar
• Jos WH. Treatment of drooling in Parkinson’s disease with botulinum toxin. Mov. Disord.14(6), 1057 (1999).
   Google Scholar
• Pal PK, Calne DB, Calne S, Tsui JK. Botulinum toxin A as treatment for drooling saliva in PD. Neurology54(1), 244–247 (2000).
   PubMedGoogle Scholar
• Friedman A, Potulska A. Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin. Parkinsonism Relat. Disord.7(4), 329–332 (2001).
   PubMed Web of Science ®Google Scholar
• Mancini F, Zangaglia R, Cristina S et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov. Disord.18(6), 685–688 (2003).
   PubMedGoogle Scholar
• Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology61(9), 1279–1281 (2003).
   PubMed Web of Science ®Google Scholar
• Racette BA, Good L, Sagitto S, Perlmutter JS. Botulinum toxin B reduces sialorrhea in parkinsonism. Mov. Disord.18(9), 1059–1061 (2003).
   PubMedGoogle Scholar
• Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology62(1), 37–40 (2004).
   PubMed Web of Science ®Google Scholar
• Dogu O, Apaydin D, Sevim S, Talas DU, Aral M. Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson’s disease. Clin. Neurol. Neurosurg.106(2), 93–96 (2004).
   PubMed Web of Science ®Google Scholar
• Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type A for drooling in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov. Disord.21(5), 704–707 (2006).
   PubMed Web of Science ®Google Scholar
• Kalf JG, Smit AM, Bloem BR, Zwarts MJ, Mulleners WM, Munneke M. Botulinum toxin A for drooling in Parkinson’s disease: a pilot study to compare submandibular to parotid gland injections. Parkinsonism Relat. Disord. (2007) (Epub ahead of print).
   Google Scholar
• Jankovic J, Hunter C, Dolimbek BZ et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology67(12), 2233–2235 (2006).
   PubMedGoogle Scholar
• Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease: frequency and pathophysiology. Neurology42, 726–732 (1992).
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol.2, 107–116 (2003).
   PubMed Web of Science ®Google Scholar
• Sakakibara R, Odaka T, Uchiyama T et al. Colonic transit time and rectoanal videomanometry in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr.74(2), 268–272 (2003).
   PubMed Web of Science ®Google Scholar
• Mathers SE, Kempster PA, Swash M, Lees AJ. Constipation and paradoxical puborectalis contraction in anismus and Parkinson’s disease: a dystonic phenomenon? J. Neurol. Neurosurg. Psychiatr.51, 1503–1507 (1988).
   PubMedGoogle Scholar
• Albanese A, Brisinda G, Bentivoglio AR, Maria G. Treatment of outlet obstruction constipation in Parkinson’s disease with botulinum neurotoxin A. Am. J. Gastroenterol.98, 1439–1440 (2003).
   PubMed Web of Science ®Google Scholar
• Cadeddu F, Bentivoglio AR, Brandara F, Marniga G, Brisinda G, Maria G. Outlet type constipation in Parkinson’s disease: results of botulinum toxin treatment. Aliment. Pharmacol. Ther.22(10), 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Barbano R, Wenqing F, Luergans S, Comella C; for the Dystonia Study Group. Utility of electromyography in botulinum toxin injection for cervical dystonia. Mov. Disord. (Suppl. 10), S19 (2005).
   Google Scholar
• Jost WH, Blumel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN®) in focal dystonia. Drugs67, 669–683 (2007).
   PubMed Web of Science ®Google Scholar
• Rieder CR, Schestatsky P, Socal MP et al. A double-blind, randomized, crossover study of Prosigne versus Botox in patients with blepharospasm and hemifacial spasm. Clin. Neuropharmacol.30, 39–42 (2007).
   PubMed Web of Science ®Google Scholar
• Naumann M, Jost W. Botulinum toxin treatment of secretory disorders. Mov. Disord.19(Suppl. 8), S137–S141(2004).
   Google Scholar
• Diamond A, Jankovic J. Botulinum toxin in dermatology – beyond wrinkles and sweat. J. Cosmet. Dermatol.5(2), 162 (2006).
   Google Scholar
• Sahai A, Khan MS, Dasgupta P; GKT Botulinum Study Group. Efficacy of botulinum toxin-a for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J. Urol.177(6), 2231–2236 (2007).
   PubMed Web of Science ®Google Scholar